Literature DB >> 17412490

Preoperative serum testosterone level as an independent predictor of treatment failure following radical prostatectomy.

Shinya Yamamoto1, Junji Yonese, Satoru Kawakami, Yuhei Ohkubo, Manabu Tatokoro, Yoshinobu Komai, Hideki Takeshita, Yuichi Ishikawa, Iwao Fukui.   

Abstract

OBJECTIVES: Preoperative low serum testosterone (TS) level has been reported to be associated with adverse pathologic results in patients with clinically localized prostate cancer (pCA) treated with radical prostatectomy (RP). However, prior studies failed to show prognostic impact of preoperative low TS in these patients. The aim of this study was to investigate the relationship between preoperative TS and prostate-specific antigen (PSA) failure in these patients.
METHODS: Of 304 patients diagnosed with clinically localized pCA who had been treated with RP alone, 272 patients whose preoperative TS level had been measured were eligible for this analysis. Postoperative TS levels were also available in 222 of the 272 patients. Cox proportional hazard model was used to elucidate factors predictive for PSA failure.
RESULTS: Of the 272 patients 49 had low (< 300 ng/dl) and 223 had normal preoperative TS level. In a stepwise multivariate analysis, preoperative TS (p = 0.021) was an independent and significant predictor of PSA failure along with RP Gleason score (p = 0.006), surgical margin status (p = 0.0001), and PSA (p = 0.0001). Five-year PSA failure-free survival rate of the patients with preoperative low TS (67.8%) was significantly worse than that with normal TS (84.9%) (p=0.035). Serum TS levels increased significantly after RP (p < 0.0001). The increment of TS level in preoperative low TS group was significantly greater than that in preoperative normal TS group (p = 0.0003).
CONCLUSIONS: The current results demonstrated that preoperative TS level is an independent and significant predictor of PSA failure after RP in patients with clinically localized pCA. European Association of Urology

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17412490     DOI: 10.1016/j.eururo.2007.03.052

Source DB:  PubMed          Journal:  Eur Urol        ISSN: 0302-2838            Impact factor:   20.096


  43 in total

1.  Apparent diffusion coefficient value as a biomarker reflecting morphological and biological features of prostate cancer.

Authors:  Hyeyeol Bae; Soichiro Yoshida; Yoh Matsuoka; Hiroshi Nakajima; Eisaku Ito; Hiroshi Tanaka; Miyako Oya; Takayuki Nakayama; Hideki Takeshita; Toshiki Kijima; Junichiro Ishioka; Noboru Numao; Fumitaka Koga; Kazutaka Saito; Takumi Akashi; Yasuhisa Fujii; Kazunori Kihara
Journal:  Int Urol Nephrol       Date:  2014-03       Impact factor: 2.370

2.  Low-risk prostate cancer and low testosterone: what are the acceptable alternatives?

Authors:  Mark Soloway
Journal:  Curr Urol Rep       Date:  2009-11       Impact factor: 3.092

Review 3.  The safety of testosterone supplementation therapy in prostate cancer.

Authors:  James M Dupree; Gavin M Langille; Mohit Khera; Larry I Lipshultz
Journal:  Nat Rev Urol       Date:  2014-07-29       Impact factor: 14.432

Review 4.  Testosterone therapy and prostate cancer--safety concerns are well founded.

Authors:  Laurence Klotz
Journal:  Nat Rev Urol       Date:  2015-01       Impact factor: 14.432

5.  Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy.

Authors:  Andrea Salonia; Firas Abdollah; Umberto Capitanio; Andrea Gallina; Nazareno Suardi; Alberto Briganti; Giuseppe Zanni; Matteo Ferrari; Fabio Castiglione; Maria Chiara Clementi; Patrizio Rigatti; Francesco Montorsi
Journal:  World J Urol       Date:  2012-03-24       Impact factor: 4.226

Review 6.  When and when not to use testosterone for palliation in cancer care.

Authors:  Rony Dev; Eduardo Bruera; Egidio Del Fabbro
Journal:  Curr Oncol Rep       Date:  2014-04       Impact factor: 5.075

Review 7.  Testosterone Therapy Among Prostate Cancer Survivors.

Authors:  Taylor M Nguyen; Alexander W Pastuszak
Journal:  Sex Med Rev       Date:  2016-07-27

Review 8.  [Testosterone replacement therapy and prostate cancer. The current position 67 years after the Huggins myth].

Authors:  L Rinnab; K Gust; R E Hautmann; R Küfer
Journal:  Urologe A       Date:  2009-05       Impact factor: 0.639

9.  Investigative clinical study on prostate cancer: on the role of the pretreatment total PSA to free testosterone ratio in selecting different biology groups of prostate cancer patients.

Authors:  Antonio B Porcaro; Filippo Migliorini; Mario Romano; Aldo Petrozziello; Stefano Zecchini Antoniolli; Emanuele Rubilotta; Vincenzo Lacola; Teodoro Sava; Claudio Ghimenton; Beatrice Caruso; Carmelo Monaco; Luigi Comunale
Journal:  Int Urol Nephrol       Date:  2009-11-10       Impact factor: 2.370

10.  Prostate size is associated with surgical difficulty but not functional outcome at 1 year after radical prostatectomy.

Authors:  Joseph A Pettus; Timothy Masterson; Alexander Sokol; Angel M Cronin; Caroline Savage; Jaspreet S Sandhu; John P Mulhall; Peter T Scardino; Farhang Rabbani
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.